PODCAST

Oncology and Hematology

ReachMD

science & medicine medicine

All Episodes

00:00:00

Personalizing Care Within the RCC Treatment Paradigm

Oncology and Hematology ·

2025/03/13

Host: Eric Jonasch, MD Guest: Brad McGregor, MD Guest: Ulka Vaishampayan, MBBS This online educational activity, derived from a live satellite symposium at ASCO GU 2025, explores the latest advances in risk stratification and evidence-based approaches for managing advanced renal cell carcinoma (RCC). Participants will gain a deeper understanding of guideline-driven treatment strategies across RCC histologies and learn strategies for the integration of multidisciplinary

00:00:00

Incorporating guideline-concordant care for patients...

Oncology and Hematology ·

2025/01/23

Host: Seema A. Bhat, MD Host: Jeremy S. Abramson, MD, MMSc This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the

00:00:00

Guideline-recommended treatment options for patients...

Oncology and Hematology ·

2025/01/23

00:00:00

Clinical trial evidence that drives current...

Oncology and Hematology ·

2025/01/23

00:00:00

Emerging data with potentially guideline-changing...

Oncology and Hematology ·

2025/01/23

00:00:00

The Evolving Role of MET TKIs in NSCLC

Oncology and Hematology ·

2024/10/02

Guest: Gilberto de Lima Lopes, Jr, MD, MBA, FASCO Guest: Jyoti Patel, MD The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). Early studies of MET tyrosine kinase inhibitors (TKIs) demonstrated limited clinical benefit; however, newer selective MET TKIs, such as capmatinib and tepotinib, have improved efficacy and

00:00:00

Chairperson's Perspective: Redefining Treatment...

Oncology and Hematology ·

2024/09/30

Host: Sara M. Tolaney, MD, MPH This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to

00:00:00

Mastering the Complexity of AML Treatment: A...

Oncology and Hematology ·

2024/09/25

Host: Amir T. Fathi, MD Guest: Courtney DiNardo, MD Guest: Brian A. Jonas, MD, PhD While the expanding arsenal of therapies available for patients with AML allows practitioners to further hone treatment and individualize care, the complexity of treatment decision-making requires careful consideration of potential risks and benefits of each treatment option. This real-world, case-based program will provide a format for community hematology-oncologists to hear current updates on

00:00:00

Noncovalent BTK Inhibitors: New Targeted Options for...

Oncology and Hematology ·

2024/09/24

Host: Matthew S. Davids, MD, MMSc This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, particularly chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and reveals crucial practice gaps. Key challenges include managing poor treatment responses and patient health deterioration, necessitating therapies that extend survival and improve quality of life. Noncovalent Bruton’s tyrosine kinase inhibitors (ncBTKi) show promise

00:00:00

MRD Testing to Guide Treatment Considerations in CLL

Oncology and Hematology ·

2024/08/16

Host: Talha Munir, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive

00:00:00

Combination Therapy in CLL: Identifying the Right...

Oncology and Hematology ·

2024/08/16

Host: Thomas Kipps, MD, PhD Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has

00:00:00

The Challenge of BCL-2 Resistance in CLL: Treatment...

Oncology and Hematology ·

2024/08/16

Host: Thomas Kipps, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive

00:00:00

Overcoming Disease Progression in CLL: Evidence-Based...

Oncology and Hematology ·

2024/08/16

00:00:00

Fixed-Duration Therapy in the Relapsed/Refractory CLL...

Oncology and Hematology ·

2024/08/16

00:00:00

Fixed-Duration vs Continuous-Dosing Approaches in...

Oncology and Hematology ·

2024/08/16

Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more

00:00:00

Frontline Fixed-Duration Therapy in CLL: Improving...

Oncology and Hematology ·

2024/08/16

00:00:00

Combination Therapy for CLL: What Evidence Do We Have?

Oncology and Hematology ·

2024/08/16

00:00:00

Mutational Testing to Guide Therapy in CLL: Why and When

Oncology and Hematology ·

2024/08/16

00:00:00

Risk-Stratification in Newly Diagnosed CLL

Oncology and Hematology ·

2024/08/16

00:00:00

Perioperative Immunotherapy for Resectable NSCLC:...

Oncology and Hematology ·

2024/06/28

Host: Mark Awad, MD, PhD This educational activity highlights the latest advancements in perioperative immunotherapy for early-stage non-small cell lung cancer and emphasizes the importance of accurate staging, molecular profiling, and a multidisciplinary approach. By integrating recent clinical trial data and expert insights, healthcare professionals will learn to evaluate and apply emerging evidence to optimize individualized treatment strategies. Explore the evolving landscape of

24 results

Oncology and Hematology

All Episodes

Similar Podcasts

Eye On The Sky

Vermont Public

Cienciaes.com

cienciaes.com

This Week in Virology

Vincent Racaniello

Hablando con Científicos - Cienciaes.com

cienciaes.com

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast

Pharmacy Joe